Further evidence of the benefits of NPC1L1 inhibition comes from naturally occurring inactivating mutations in the NPC1L1 gene, which have been shown to reduce both LDL-C and ASCVD risk [26]. The gene discussed is NPC1L1; the disease is atherosclerosis.